Speaker Lecture Titles
Partial list of confirmed speakers.
Name |
Country |
Lecture Title |
|---|---|---|
| Claudio A. Cuello | Canada | NEW PERSPECTIVES OF NGF METABOLISM AND THE CHOLINERGIC SYSTEM IN PRECLINICAL ALZHEIMER’S |
| Liana Apostolova | USA | SPORADIC EARLY-ONSET ALZHEIMER’S DISEASE: PRELIMINARY LONGITUDINAL RESULTS FROM LEADS |
| Johannes Attems | UK | AGE ASSOCIATED TDP-43 PATHOLOGY |
| Tom Beach | USA | BIOPSIES FOR DIAGNOSTIC AND PROGRESSION BIOMARKERS IN NEURODEGENERATIVE DISEASE |
| Mathew Blurton Jones | USA | EXAMINING THE THERAPEUTIC POTENTIAL OF CRISPR-MODIFIED IPS-MICROGLIA |
| Mercè Boada | Spain | TBA |
| Guojun Bu | USA | CENTRAL AND PERIPHERAL APOE IN ALZHEIMER’S DISEASE |
| Samantha Budd-Haeberlein | USA | DEVELOPMENT OF THERAPEUTICS IN ALZHEIMER’S DISEASE |
| Luc Buee | France | TAU IMMUNOTHERAPY: INTRACELLULAR OU EXTRACELLULAR TARGET? |
| Frédéric Checler | France | BETA-SECRETASE-DERIVED C-TERMINAL FRAGMENTS OF BETA-APP AS EARLY TRIGGERS OF CELLULAR DYSFUNCTIONS AND ANATOMICAL STIGMATA IN ALZHEIMER’S DISEASE |
| Gaël Chételat | France | IMPACT OF PSYCHOAFFECTIVE FACTORS ON ALZHEIMER’S DISEASE RISK AND MEDITATION AS AN PROMISING PREVENTIVE APPROACH |
| Ornit Chiba-Falek | USA | MULTI-OMICS NAVIGATION OF ALZHEIMER’S AND PARKINSON’S GENETIC LANDSCAPES FROM SINGLE-CELL LENSES |
| Don Cleveland | USA | TRACING GLIA-INTO-NEURON CONVERSION IN THE AGED MOUSE BRAIN USING SINGLE CELL SPATIAL TRANSCRIPTOMICS |
| Jeffrey Cummings | USA | THE ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE: THE CHANGING THERAPEUTIC LANDSCAPE |
| Bart De Strooper | Belgium | THE EARLY CELLULAR RESPONSES IN THE ALZHEIMER DISEASE BRAIN. |
| Marc Diamond | USA | DETERMINATION OF AMINO ACIDS CRITICAL TO TAU ASSEMBLY IN TAUOPATHIES |
| Karen Duff | UK | PATHOGENIC MECHANISMS IN THE TAUOPATHIES |
| Adam Fleisher | USA | EVOLUTION TOWARDS PRACTICAL BIOMARKERS FOR RESEARCH AND DIAGNOSIS IN ALZHEIMER’S DISEASE |
| Nick Fox | United Kingdom | ULTRAFAST MRI AND BIOMARKERS TO IMPROVE DIAGNOSIS RATES IN DEMENTIA |
| Dan Frenkel | Israel | THE LINK BETWEEN TAU TO BETA-AMYLOID: THE ASTROCYTES PERSPECTIVE |
| Giovanni Frisoni | SWITZERLAND | THE MEMORY CLINIC OF THE FUTURE: BRAIN HEALTH SERVICES FOR SECONDARY PREVENTION OF DEMENTIA AND COGNITIVE IMPAIRMENT |
| James Galvin | USA | BUILDING A BETTER BRAIN – USING PRECISION MEDICINE APPROACHES FOR DEMENTIA PREVENTION RESEARCH |
| Angela Genge | Canada | THE EVOLUTION OF BIOMARKERS AND OUTCOME MEASURES IN ALS DRUG DEVELOPMENT |
| Klaus Gerwert | Germany | PROTEIN MISFOLDING AS BIOMARKER FOR ALZHEIMER´S DISEASE, PARKINSON´S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS |
| Alison Goate | USA | ALZHEIMER’S DISEASE GENETICS IMPLICATES EFFEROCYTOSIS AND A DISEASE RISK HUB |
| Gabriel Gold | Switzerland | MICROVASCULAR LESIONS: THE CONCEALED THREAT TO OLD AGE COGNITION. |
| Todd Golde | USA | THE AMYLOID SCAFFOLD HYPOTHESIS |
| Maria Grazia Spillantini | UK | ASSOCIATION OF TMEM106B WITH HUMAN AGING |
| John Growdon | USA | TREATING DLB: CURRENT PRACTICE AND FUTURE DIRECTIONS |
| Christian Haass | Germany | MICROGLIAL FUNCTION AND DYSFUNCTION IN AD |
| Harald Hampel | USA | DESIGNING THE NEXT GENERATION CLINICAL CARE AND DIAGNOSTIC PATHWAY FOR ALZHEIMER’S DISEASE |
| Oskar Hansson | Sweden | FLUID AND IMAGING BIOMARKERS FOR ALZHEIMER’S AND PARKINSON’S DISEASES |
| Susanne Hendrix | USA | BUYING BACK TIME: THE UNIQUE TREATMENT IMPLICATIONS OF DISEASE MODIFYING THERAPIES |
| Michael Heneka | Germany | INNATE IMMUNE METABOLISM DETERMINES MICROGLIAL Aß CLEARANCE CAPACITY |
| Joachim Herz | USA | THE EARLY ENDOSOME: A THERAPEUTIC HUB FOR THE PREVENTION OF ALZHEIMER’S DISEASE |
| Makato Higuchi | Japan | IN-VIVO IMAGING OF PROTEIN AGGREGATES IN DIVERSE NEURODEGENERATIVE DISORDERS: RELATION TO STRUCTURES OF PATHOLOGICAL FILAMENTS |
| Henne Holstege | The Netherlands | ESCAPING COGNITIVE DECLINE UNTIL EXTREME AGES: AN OMICS-STUDY OF COGNITIVELY HEALTHY CENTENARIANS |
| David Holtzman | USA | MICROGLIA-MEDIATED T CELL INFILTRATION DRIVES NEURODEGENERATION IN TAUOPATHY |
| Bradley Hyman | USA | UNDERSTANDING HETEROGENEITY IN ALZHEIMER DISEASE |
| Costantino Iadecola | USA | BORDER ASSOCIATED MACROPHAGES TAKE CENTER STAGE IN THE NEUROVASCULAR DYSFUNCTION OF APOE4 |
| Ole Isaacson | USA | LIPID LOAD, EXCHANGE AND STORAGE INVOLVED IN THE DISEASE PROCESSES OF LEWY BODY DEMENTIA |
| Takeshi Iwatsubo | Japan | PET AND BIOMARKER CHARACTERIZATION OF PRECLINICAL AD IN THE JAPANESE TRIAL READY COHORT |
| Clifford Jack | USA | IN DEFENSE OF A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE |
| William Jagust | USA | ASSOCIATIONS WITH TAU AND COGNITION IN PRECLINICAL ALZHEIMER’S DISEASE |
| Beomseok Jeon | Korea | A MULTICENTER, CASE-CONTROL STUDY OF Α-SYNUCLEIN ACCUMULATION IN THE GASTROINTESTINAL TRACT OF PARKINSON’S DISEASE |
| Jonathan Kipnis | USA | THE ROLE OF BRAIN BORDERS IN AD |
| Frank Laferla | USA | MODELING LATE-ONSET ALZHEIMER’S DISEASE IN MICE |
| Susan Landau | USA | TAU HETEROGENEITY IN ALZHEIMER’S DISEASE |
| Virginia Lee | USA | IN VITRO AND IN VIVO AMPLIFICATION OF PATHOLOGICAL AD-TAU AND LBD-A-SYNUCLEIN |
| Seung-Jae Lee | Korea | NEUROINFLAMMATION DRIVES COMPOUND PROTEINOPATHIES |
| Cynthia Lemere | USA | C3 LOWERING IN ADULT MICE PROTECTS AGAINST AGE-RELATED NEURODEGENERATION |
| Gregg Lemke | USA | THE DENSE-CORE PLAQUES OF ALZHEIMER’S DISEASE ARE GRANULOMAS |
| Stuart Lipton | USA | INHIBITION OF AUTOPHAGIC FLUX BY ABERRANT PROTEIN S-NITROSYLATION PROMOTES NEURONAL SECRETION AND CELL-TO-CELL TRANSMISSION OF AGGREGATED PROTEINS IN PARKINSON’S DISEASE/LEWY BODY DEMENTIA AND ALZHEIMER’S DISEASE |
| Eva Mandelkow | Germany | TREATMENTS AND REVERSAL OF TAU PATHOLOGY IN TRANSGENIC MICE |
| Eckhard Mandelkow | Germany | TAU PROTEIN: POSTTRANSLATIONAL MODIFICATIONS, AGGREGATION, AND CONDENSATION |
| Ken Marek | USA | DEVELOPING PD PRODROMAL BIOMARKER SIGNATURE TO SUPPORT PRODROMAL THERAPEUTIC TRIALS |
| Eliezer Masliah | USA | THE INTERPLAY BETWEEN AGING, THE IMMUNE SYSTEM AND ALPHA-SYNUCLEIN IN THE PATHOGENESIS OF DLB/PD |
| Pamela McLean | USA | PD THERAPIES TARGETING ALPHA-SYNUCLEIN |
| Daniel Michaelson | Israel | COUNTERACTING THE PATHOLOGICAL EFFECTS OF APOE4 BY ACTIVATION OF THE LIPIDATING PROTEIN ABCA1 |
| Mark Mintun | USA | POTENTIAL ROLE OF PRECISION MEDICINE APPROACHES IN USING AMYLOID TARGETING THERAPIES |
| Asuka Morizane | Japan | MONITORING GRAFT SURVIVAL AND IMMUNE RESPONSE IN CELL REPLACEMENT THERAPY FOR PARKINSON’S DISEASE |
| John Morris | USA | ALZHEIMER BIOMARKER CORRELATIONS WITH MEASURES OF SOCIAL DETERMINANTS OF HEALTH |
| Ulrike Müller | Germany | HARNESSING THE PHYSIOLOGICAL FUNCTIONS OF APP FOR AD TREATMENT |
| Manuela Neumann | Germany | DISSECTING THE ROLE OF OLIGODENDROCYTES IN TDP-43 PROTEINOPATHIES |
| Henrietta Nielsen | Sweden | PERIPHERAL APOE-RELATED SIGNATURES |
| Tania Nikolcheva | Switzerland | LESSONS LEARNED FROM CLINICAL TRIALS IN ALZHEIMER’S AND PARKINSON’S DISEASES |
| Agneta Nordberg | Sweden | THE CLINICAL VALUE OF PLASMA BIOMARKERS IN A TERITARY MEMORY CLINIC – A COMPARISON WITH IMAGING AND CSF BIOMARKERS |
| Miranda Orr | USA | CELLULAR SENESCENCE AS A PATHOGENIC CONTRIBUTOR AND THERAPEUTIC TARGET IN ALZHEIMER’S DISEASE |
| Tiago Outerio | Germany | GLYCATION AS A TARGET FOR INTERVENTION IN SYNUCLEINOPATHIES |
| Ronald Petersen | USA | FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT |
| Werner Poewe | Austria | EVOLVING CONCEPTS IN THE DIAGNOSIS OF PD |
| Marco Prado | Canada | IMPROVING RESEARCH TRANSLATION IN DEMENTIA: HUMANIZED MOUSE MODELS, COGNITION AND IMAGING |
| Gill Rabinovici | USA | ALZ-NET: A U.S.-WIDE REGISTRY TO TRACK LONGITUDINAL OUTCOMES IN PATIENTS TREATED WITH NOVEL AD THERAPIES IN REAL WORLD CLINICAL PRACTICE |
| Laura Ranum | USA | INTRONIC GGGAGA EXPANDED REPEATS IN CASP8 PRODUCE POLYGLYCINEARGININE PROTEINS THAT ACCUMULATE IN ALZHEIMER’S BRAINS AND INCREASE RISK OF DISEASE |
| Stephen Salloway | USA | NEW AND EMERGING TREATMENTS FOR ALZHEIMER’S DISEASE |
| Philip Scheltens | The Netherlands | ALZHEIMER: THE SEARCH FOR BETTER TARGETS AND MEANINGFUL OUTCOMES |
| Sjors Scheres | UK | CRYO-EM STRUCTURES OF AMYLOIDS FROM HUMAN BRAIN |
| Michael Schlossmacher | Canada | EXAMINATION OF THE OLFACTORY EPITHELIUM AND CRANIAL NERVE-1 IN AUTOPSY CASES OF COVID19 AND NEURODEGENERATION |
| Taylor Schmitz | Canada | TRANSLATIONAL POTENTIAL FOR MULTIMODAL IMAGING OF CHOLINERGIC PHENOTYPES IN MICE |
| Julie Schneider | USA | NEUROPATHOLOGY OF COGNITIVE AGING. WHAT TIPS THE BALANCE? |
| Menachem Segal | Israel | PRESENILIN AFFECTS MITOCHONDRIAL FUNCTIONS IN CULTURED HIPPOCAMPAL NEURONS: IMPLICATIONS FOR ALZHEIMER’S DISEASE |
| Jie Shen | USA | NOVEL THERAPIES OF FAMILIAL ALZHEIMER’S DISEASE |
| Tamara Shiner | Israel | IMAGING MARKERS IN GBA RELATED DEMENTIA WITH LEWY BODIES |
| Sam Sisodia | USA | THE GUT MICROBIOME MODULATES AD-LIKE PHENOTYPES IN MOUSE MODELS |
| Beka Solomon | Israel | ALZHEIMER’S DISEASE AND IMMUNOTHERAPY |
| Mona Soreq | Israel | TRANSFER RNA FRAGMENTS CARRYING A COMMON SEQUENCE MOTIF CAUSE SUPPRESSIBLE PARKINSON’S DISEASE NEURONAL DEATH VIA TRANSLATIONAL ARREST |
| Reisa Sperling | USA | AMYLOID, TAU, AND COGNITIVE DECLINE DURING THE PRECLINICAL STAGES OF ALZHEIMER’S DISEASE |
| Peter St. George-Hyslop | Canada | ROLE OF MICROGLIAL RISK AND RESILIENCE GENES IN REGULATING MICROGLIAL SIGNALLING AND FUNCTION |
| Beth Stevens | USA | NEUROIMMUNE MECHANISMS OF ALZHEIMER’S DISEASE : MAPPING GENETIC VARIANT TO FUNCTION IN BRAIN ASSOCIATED MACROPHAGES |
| Fabrizio Stocchi | Italy | NEW INSIGHT IN THE TREATMENT OF PARKINSONS DISEASE |
Thomas Sudhof
 Nobel Prize Winner |
USA | CONNECTING LIPID METABOLISM TO SYNAPTIC DYSFUNCTION IN ALZHEIMER’S DISEASE |
| Malu Tansey | USA | TARGETING INNATE IMMUNE DYSFUNCTION AND CHRONIC INFLAMMATION IN THE GUT-BRAIN AXIS TO LOWER RISK AND PROGRESSION OF NEURODEGENERATION |
| Rudy Tanzi | USA | ALZHEIMER’S DISEASE IS A GENETICALLY COMPLEX AND HETERGENEOUS INNATE IMMUNE DISORDER |
| Maria Teresa Ferretti | Switzerland | LEVERAGING SEX DIFFERENCES FOR IMPROVED PREVENTION, DIAGNOSTICS AND TREATMENT – THE WORK OF THE WOMEN’S BRAIN PROJECT |
| Li-Huei Tsai | USA | LIPID DYSREGULATION IS A COMMON PATHOGENIC MECHANISM OF MAJOR ALZHEIMER’S DISEASE RISK GENES |
| Christine Van Broeckhoven | Belgium | CONTRIBUTION OF RARE GENETIC VARIANTS TO NEURODEGENERATIVE BRAIN DISEASES |
| Robert Vassar | USA | ANNEXIN A6 OVEREXPRESSION REDUCES DYSTROPHIC NEURITE FORMATION AND PATHOLOGIC TAU PHOSPHORYLATION IN 5XFAD MICE |
| Yaning Wang | USA | FACTS AND MISCONCEPTIONS ABOUT ADUCANUMAB APPROVAL |
| Carina Wattmo | SWEDEN | SEX DIFFERENCES IN DISEASE PROGRESSION IN ALZHEIMER PATIENTS WITH DIFFERENT CONCOMITANT MEDICATIONS |
| Howard L. Weiner | USA | IMMUNOTHERAPY OF ALZHEIMER’S DISEASE BY MODULATION OF INNATE IMMUNITY |
| Michael Weiner | USA | USING DIGITAL AND FLUID BIOMARKERS FOR SCREENING AND SELECTION INTO THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE |
| Cheryl Wellington | Canada | LIPOPROTEINS IN ALZHEIMER’S DISEASE |
| Donna Wilcock | USA | DISEASE INSIGHTS FROM NOVEL PLASMA BIOMARKERS OF MULTI-ETIOLOGY DEMENTIA |
| Bengt Winblad | SWEDEN | DEVELOPMENT OF TREATMENT WITH SMALL MOLECULES FOR ALZHEIMER DISEASE |
| Henrik Zetterberg | Sweden | THE USE OF BLOOD BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIAL OUTCOMES |
| Jiawei Zhou | China | NON-CANONICAL ROLE OF INTESTINAL DOPAMINE RECEPTOR SIGNALLING IN NEURODEGENERATION |
| Berislav Zlokovic | USA | BLOOD-BRAIN BARRIER ROLE IN NEURODEGENERATION, COGNITIVE DECLINE AND ALZHEIMER’S DISEASE |